SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1

Abstract

Adipocytes are the most abundant cell type in the adipose tissue, and their dysfunction is a significant driver of obesity-related pathologies, such as cancer. The mechanisms that (1) drive the maintenance and secretory activity of adipocytes and (2) mediate the cancer cellular response to the adipocyte-derived factors are not fully understood. To address that gap of knowledge, we investigated how alterations in Src homology region 2-containing protein (SHP2) activity affect adipocyte function and tumor crosstalk. We found that phospho-SHP2 levels are elevated in adipose tissue of obese mice, obese patients, and differentiating adipocytes. Immunofluorescence and immunoprecipitation analyses as well as in-silico protein–protein interaction modeling demonstrated that SHP2 associates with PDHA1, and that a positive association promotes a reactive oxygen species (ROS)-driven adipogenic program. Accordingly, this SHP2-PDHA1-ROS regulatory axis was crucial for adipocyte maintenance and secretion of interleukin-6 (IL-6), a key cancer-promoting cytokine. Mature adipocytes treated with an inhibitor for SHP2, PDHA1, or ROS exhibited an increased level of pro-lipolytic and thermogenic proteins, corresponding to an increased glycerol release, but a suppression of secreted IL-6. A functional analysis of adipocyte-cancer cell crosstalk demonstrated a decreased migration, invasion, and a slight suppression of cell cycling, corresponding to a reduced growth of pancreatic cancer cells exposed to conditioned media (CM) from mature adipocytes previously treated with inhibitors for SHP2/PDHA1/ROS. Importantly, PDAC cell growth stimulation in response to adipocyte CM correlated with PDHA1 induction but was suppressed by a PDHA1 inhibitor. The data point to a novel role for (1) SHP2-PDHA1-ROS in adipocyte maintenance and secretory activity and (2) PDHA1 as a regulator of the pancreatic cancer cells response to adipocyte-derived factors.

Comparison of Deeply Versus Mildly Invasive Mesothelioma Proteomes Identifies Potential Links Between Mitochondrial Acadvl Expression and Biomarkers of Aggressiveness

“…First, Deng et al revealed that it could represent a prognostic and immune-associated biomarker in multiple cancers, its expression being linked to DNA damage, cell invasion, and angiogenesis [26]. A second study by Olou et al pointed to its involvement in adipocyte maintenance and secretion of the cancer-promoting cytokine IL-6 [27]. Finally, Tian et al showed that silencing this gene suppressed proliferation, migration, and invasion in neuroblastoma [28].…”

Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?

“…Fedele et al (95) discovered that SHP2 inhibition reduced RTK feedback signals and enhanced the action of KRAS G12C inhibitors in PDAC. Furthermore, the SHP2-PDHA1-ROS axis is crucial for the upkeep of adipocytes and may regulate cytokine production as well as the proliferation of pancreatic cancer cells (96). Consequently, the majority of recent research points to a favorable association between SHP2 and the onset and progression of PDAC, indicating that SHP2 might be a desirable target in treatment combinations for this predominantly KRASmutated entity.…”

Insights into prognosis and immune infiltration of cuproptosis-related genes in breast cancer

“…Some evidence suggested PDHA1 was closely related to the progression and prognosis of gastric, pancreatic and esophageal squamous cancer (31)(32)(33). Therefore, we performed Kaplan-Meier analysis between CRGs expression and survival outcomes in BC, including OS and RFS.…”